Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nabilone target engagement in OCD
NCT04880278Phase 2Withdrawn
- Sponsor
- New York State Psychiatric Institute
- Start
- Mar 2022
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obsessive compulsive disorder (OCD) comparing Nabilone with Placebo (2 arms). Primary endpoints: Brain Measure 1 at 5 years, Brain Measure 2 at 5 years and 3 more. Planned start Mar 2022; status: withdrawn.
02
Drugs
nabilone
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT04880278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04880278.